| Stock Symbol | NYSE: CTLT |
|---|---|
| Headquarters | Somerset, New Jersey, USA |
| Founded | 2007 (spin-off from Cardinal Health) |
| Revenue | $4.38 billion (FY 2024) |
| CEO | Alessandro Maselli (President & CEO) |
| Employees | ~13,500 globally |
| Focus Areas | Oral dose, biologics, clinical supply, cell & gene therapy |
Catalent Pharma Solutions is a leading global Contract Development and Manufacturing Organization (CDMO) that partners with pharmaceutical, biotech, and consumer health companies to accelerate drug development, manufacturing, and clinical supply solutions. Headquartered in Somerset, New Jersey, with operations spanning more than 50 sites across North America, Europe, and Asia, Catalent plays a critical role in the global pharmaceutical supply chain for neurodegeneration therapeutics[1].
Founded in 2007 as a spin-off from Cardinal Health's pharmaceutical technologies segment, Catalent has grown to become one of the largest and most diversified CDMOs in the world. The company went public on the New York Stock Exchange in 2014 (NYSE: CTLT) and has since expanded through strategic acquisitions. In 2024, Catalent was acquired by an investor consortium led by Blackstone for approximately $16 billion, marking one of the largest private equity transactions in the pharmaceutical services sector[2].
Catalent's relevance to Alzheimer's disease and neurodegeneration drug development stems from its comprehensive suite of drug development platforms, including advanced oral dose formulation (softgel capsules, controlled release), biologics manufacturing (monoclonal antibodies, cell & gene therapy), and specialized clinical supply services that are particularly critical for complex CNS clinical trials[3].
Catalent operates through four primary business segments that collectively support neurodegeneration drug development:
The Oral Dose Solutions segment is the company's largest and most mature business unit, providing comprehensive formulation development and manufacturing services for oral pharmaceuticals. This segment includes:
Relevance to AD: Many Alzheimer's disease drugs require sophisticated oral delivery systems. For example, drugs requiring enhanced brain penetration through active transport mechanisms benefit from Catalent's controlled release and permeability enhancement platforms. Several AD programs in development leverage these capabilities[5].
The Biologics segment has grown substantially and now represents Catalent's fastest-growing business unit, driven by the shift toward large molecule therapeutics in neurodegeneration:
Relevance to AD: The success of amyloid-targeting antibodies like lecanemab and donanemab has driven significant investment in anti-amyloid and anti-tau antibody programs. These antibodies require mammalian cell manufacturing, sterile fill/finish, and cold-chain distribution — all capabilities that Catalent provides. The biologics segment supports numerous pre-clinical and clinical-stage antibody programs targeting Alzheimer's disease mechanisms[6].
The Clinical Supply segment provides integrated services for managing global clinical trials, which is particularly critical for neurodegeneration programs that often involve:
Relevance to AD: Alzheimer's disease clinical trials are among the most complex in drug development, typically involving 18-24 month treatment periods, biomarker-focused endpoints, and multi-site international enrollment. These trials require sophisticated clinical supply chain management that Catalent provides, including specialized packaging for cognitive assessment kits and biomarker sample collection materials[7].
Catalent has built significant capabilities in advanced therapy manufacturing:
Relevance to AD: While cell and gene therapy for Alzheimer's disease remains largely in pre-clinical stages, several companies are exploring AAV-mediated delivery of neurotrophic factors, gene editing approaches targeting risk genes (APOE4, TREM2), and cell replacement therapies using engineered neural progenitors. Catalent's cell and gene therapy facilities provide manufacturing capacity for these emerging programs.
Catalent operates a network of manufacturing facilities across three continents:
| Facility Location | Primary Capabilities | Certifications |
|---|---|---|
| Somerset, NJ, USA | Oral dose, clinical supply | FDA, EMA, PMDA |
| Bloomington, IN, USA | Biologics fill/finish | FDA, EMA |
| Kansas City, MO, USA | Oral dose (softgels) | FDA, EMA |
| Reading, UK | Biologics, fill/finish | EMA, MHRA |
| Eberbach, Germany | Oral dose, packaging | EMA |
| Anagni, Italy | Oral dose, softgels | EMA |
| Bangkok, Thailand | Clinical supply Asia | FDA, EMA |
| Shanghai, China | Oral dose, biologics | NMPA, FDA |
Catalent's softgel capsule manufacturing is widely recognized as best-in-class:
This technology is directly relevant to several categories of Alzheimer's disease drugs, including BACE inhibitors requiring enteric coating for stability, PPAR agonists often lipid-based formulations, and anti-inflammatory nutraceuticals in development for MCI/early AD.
Catalent's biologics capabilities include:
Upstream Manufacturing:
Downstream Processing:
Fill/Finish:
Catalent partners with numerous companies developing neurodegeneration therapeutics[8]:
Monoclonal Antibody Programs:
Oral CNS Programs:
Catalent serves as a critical manufacturing partner for major pharmaceutical companies[9]:
| Client Type | Services Provided | AD Relevance |
|---|---|---|
| Large pharma (top 20) | Commercial oral dose, biologics fill/finish | Legacy AD programs, new antibodies |
| Biotech (mid-size) | Clinical supply, process development | Novel mechanisms, targeted therapies |
| Virtual companies | End-to-end development services | Asset development, licensing |
| Generic companies | Commercial manufacturing | Generic AD treatments |
Major customer relationships include partnerships with Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics, several of whom have active neurodegeneration programs.
| Fiscal Year | Revenue (USD) | Key Growth Drivers |
|---|---|---|
| 2024 | $4.38 billion | Biologics expansion, clinical supply |
| 2023 | $4.08 billion | Softgel capacity, Asia expansion |
| 2022 | $3.86 billion | COVID-related services wind-down |
Catalent has made significant capital investments to expand neurodegeneration-relevant capabilities:
| CDMO | Key Strengths | AD Capabilities |
|---|---|---|
| Catalent | Softgel, biologics, clinical supply | Full-service, global |
| Lonza | Mammalian manufacturing, microbial | Strong biologics |
| Thermo Fisher (Patheon) | End-to-end, API manufacturing | Broad, integrated |
| Cambrex | API development, controlled substances | Small molecules |
| Siegfried | Oral dose, injectables | Mid-scale |
Catalent maintains competitive differentiation through its breadth of capabilities, particularly the combination of oral dose expertise, biologics manufacturing, and clinical supply services that many competitors cannot match as a single provider.
Catalent Pharma Solutions — Delivering Better Treatments. 2025. ↩︎
Catalent Pharma Solutions. 2025. ↩︎
Bioinsilico Knowledgebase. Catalent Pharma Solutions — CDMO Capabilities Assessment. Drug Discovery Today. 2023. ↩︎
Softgel Technology Consortium. Advances in Softgel Capsule Technology for CNS Therapeutics. Int J Pharm. 2022. ↩︎
Oral Dose Forum. Oral Delivery Strategies for Alzheimer's Disease Therapeutics. Adv Drug Deliv Rev. 2024. ↩︎
PharmaDeals Analysis. Biologics Manufacturing Partnerships in Neurodegeneration 2024. Nat Biotechnol. 2024. ↩︎
ClinReg Consulting. Clinical Supply Chain Optimization for CNS Trials. Contemp Clin Trials. 2023. ↩︎
NeuroPipeline Analytics. Alzheimer's Disease Drug Pipeline Analysis 2024. Alzheimers Dement. 2024. ↩︎
Partnership Intelligence Group. Major CDMO Partnerships in CNS Drug Development 2023-2024. J Pharm Sci. 2024. ↩︎